According to reports, Merck is in talks to acquire biotechnology company MoonLake for over $3 billion

AASTOCKS
2025.06.02 21:23

According to the Financial Times, Merck (MRK.US) is in negotiations to acquire the Swiss biotechnology company MoonLake Immunotherapeutics, with the acquisition price expected to exceed $3 billion

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.